Avantor｜8-K：2025 财年 Q2 营收 16.83 亿美元超过预期

Revenue: As of FY2025 Q2, the actual value is USD 1.683 B, beating the estimate of USD 1.675 B.

EPS: As of FY2025 Q2, the actual value is USD 0.09, missing the estimate of USD 0.1439.

EBIT: As of FY2025 Q2, the actual value is USD 128.8 M.

Segment Revenue

• Laboratory Solutions: Net sales were $1,122.1 million, a reported decrease of 3% compared to $1,155.7 million in the second quarter of 2024. Organic sales declined by 1% after accounting for a 2% positive impact from foreign currency translation and a 4% negative impact from M&A.
• Bioscience Production: Net sales were $561.3 million, a reported increase of 3% compared to $547.1 million in the second quarter of 2024. Organic sales increased by 2% after a 1% positive impact from foreign currency translation.

Operational Metrics

• Net Income: Decreased to $64.7 million from $92.9 million in the second quarter of 2024, with a net income margin of 3.8%.
• Adjusted EBITDA: $279.8 million, with an adjusted EBITDA margin of 16.6%.
• Adjusted Operating Income: $252.2 million, with an adjusted operating income margin of 15.0%.

Cash Flow

• Operating Cash Flow: $154.4 million.
• Free Cash Flow: $125.4 million.

Unique Metrics

• Adjusted Net Leverage: 3.2x as of June 30, 2025.

Outlook / Guidance

Avantor, Inc. remains focused on driving growth and enhancing operating leverage, with initiatives in place to mitigate challenges in the Bioscience Production segment. The company is optimistic about the strength of its core monoclonal antibody platform and its ability to deliver long-term shareholder value through operational excellence and strong customer relationships.